The Miami Myeloma MRD Virtual Meeting 2024 take places on 9 May at 9am – 1pm EST/2pm – 6pm BST/3pm – 7pm CEST.

Hosted by the Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, in collaboration with the Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), and HealthTree Foundation for Multiple Myeloma, with VJHemOnc as official media partner.

The workshop will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.

Chaired by Ola Landgren, MD, Sylvester Comprehensive Cancer Center

Agenda (All times in EST)

9:00-9:05AM
Live welcome and intro – Ola Landgren

9:05-9:55AM
SESSION I: Current era of MRD testing

• PERSEUS study – depth and timing of MRD negativity in newly dx myeloma when using Dara-RVd: Pieter Sonneveld
• ISKIA study – MRD negativity in high-risk newly dx myeloma when using Isa-KRd: Francesca Gay
• REMNANT study – treating myeloma at MRD relapse?: Fredrik Schjesvold
• MRD and plasma cell dynamics after CAR T-cells in myeloma: Martin Kaiser

Live Q&A – session chair: Damian Green

9:55-10:15AM
Live discussion – how to have an MRD conversation between physician and patient: Yelak Biru (IMF), Joseph Mikhael and Ola Landgren

10:15-11:05AM
SESSION II: Current and emerging technologies for tracking MRD in myeloma

• Single-cell analysis of myeloma through the Immune Atlas: Sacha Gnjatic
• Updates on individualized serum peptides for MRD tracking: Katie Thoren
• Ultrasensitive detection of circulating tumor DNA using CAPP sequencing: Hitomi Hosoya
• Whole genome sequencing of circulating myeloma cells in the blood: Irene Ghobrial

Live Q&A – session chair: David Coffey

11:05-11:25AM
Live discussion – perspectives on available and new MRD assays in myeloma: George Mulligan (MMRF) and Ola Landgren

11:25-11:45AM
Fireside chat with the FDA – what is happening in MRD in myeloma; what is next?: Nicole Gormley (FDA) and Ola Landgren

11:45AM-12:35PM
SESSION III: Myeloma MRD testing in the real world?

• Updates on the MASTER trial treatment cessation study: Luciano Costa
• Updates on the Chicago treatment cessation study: Benjamin Derman
• Updates on the MSKCC treatment cessation study: Neha Korde
• Updates on the UK NCRI Myeloma XI trial; (when) can you stop maintenance therapy?: Charlotte Pawlyn

Live Q&A – session chair: Dickran Kazandjian

12:35-12:55PM
Live discussion: using MRD in the real world: Jennifer Ahlstrom (HealthTree) and Ola Landgren

12:55-1:00PM
Live wrap-up and adjourn – Yelak Biru (IMF), George Mulligan (MMRF), Jennifer Ahlstrom (HealthTree), and Ola Landgren

The Miami Myeloma MRD 2024 Workshop is supported by: